Mozavaptan is an oral vasopressin V2 antagonist that has been launched in
Japan for inappropriate antidiuretic hormone secretion syndrome (IADHS), an
affliction manifesting as hyponatremia. It joins another nonpeptidic benzazepine,
conivaptan, which corrects sodium and water imbalance by blocking the renal V2
receptor resulting in enhanced diuresis, thereby effectively increasing serum
sodium concentration. While conivaptan inhibits both V1 and V2 receptors,
mozavaptan is significantly more selective for V2 (IC50 of 14nM vs. 1.2 mM for
V1).
